-
1.发明授权Pharmaceutical compositions including alginates and methods of preparing and using same 失效包括藻酸盐的药物组合物及其制备和使用方法公开(公告)号：US07776839B2
公开(公告)日：2010-08-17
申请号：US10241048
申请日：2002-09-10
申请人： Raffaele Del Buono , Peter William Dettmar , Frank Chadwick Hampson , Ian Gordon Jolliffe , Paul Murray McPherson , Edvar Onsoyen , Massimo Pignatelli , Peter Edward Ross
发明人： Raffaele Del Buono , Peter William Dettmar , Frank Chadwick Hampson , Ian Gordon Jolliffe , Paul Murray McPherson , Edvar Onsoyen , Massimo Pignatelli , Peter Edward Ross
IPC分类号： A51K31/734
CPC分类号： A61K31/7012 , A61K31/734
摘要： A pharmaceutical composition is provided for use in the healing of cells containing about 0.0001 percent weight per volume (% w/v) to about 2% w/v of an alginic acid or a salt of alginic acid having a molecular weight in the range of greater than about 250,000 to about 1,000,000, provided that if the composition additionally contains an alginic acid or a salt of alginic acid having a molecular weight in the range of about 20,000 to about 250,000, it is present in an amount of less than 1% w/w. The use of the pharmaceutical composition for the healing cells in a mammal, preferably mucosal cells is also provided.
摘要翻译： 提供了用于治疗细胞的药物组合物，其含有约0.0001重量％体积（％w / v）至约2％w / v的海藻酸或藻酸盐，其分子量范围为 大于约250,000至约1,000,000，条件是如果组合物另外含有分子量在约20,000至约250,000范围内的藻酸或海藻酸盐，则其存在量小于1％w / w。 还提供了用于哺乳动物，优选粘膜细胞中的愈合细胞的药物组合物的用途。
-
公开(公告)号：US06395307B1
公开(公告)日：2002-05-28
申请号：US09403217
申请日：1999-12-17
申请人： Douglas Banning , Peter William Dettmar , Ian Gordon Jolliffe , Frank Chadwick Hampson , Edvar Jarle Onsoyen , Paul Frederick Field , Duncan Quinell MacKenzie Craig , Ase Hanne Kristensen
发明人： Douglas Banning , Peter William Dettmar , Ian Gordon Jolliffe , Frank Chadwick Hampson , Edvar Jarle Onsoyen , Paul Frederick Field , Duncan Quinell MacKenzie Craig , Ase Hanne Kristensen
IPC分类号： A61K3300
CPC分类号： A61K9/0065 , A61K9/0095 , A61K31/734 , A61K33/10 , Y10S514/925 , Y10S514/927 , A61K2300/00
摘要： An aqueous pourable liquid composition comprising a high concentration of sodium alginate and an alkali metal bicarbonate, wherein the sodium alginate has an average mannuronic acid residue to guluronic acid residue ratio of at least 0.6:1. In addition, an alginate or alginic acid for forming a protective coating on gastrointestinal mucosal tissue, use of and compositions including the same are provided.
摘要翻译： 一种包含高浓度海藻酸钠和碱金属碳酸氢盐的水溶性液体组合物，其中藻酸钠具有至少0.6:1的平均甘露糖醛酸残基与古洛糖醛酸残基之比。 此外，提供了用于在胃肠粘膜组织上形成保护性涂层的藻酸盐或藻酸，其用途和包含其的组合物。
-
公开(公告)号：US06610667B1
公开(公告)日：2003-08-26
申请号：US09979538
申请日：2002-01-07
IPC分类号： A61K31715
CPC分类号： A61K9/0065 , A61K31/736 , A61K31/715
摘要： Pharmaceutical compositions having improved bioadhesive properties are produced by combining an alginate, xanthan gum and/or a carageenan gum and a glucomannan and/or a galactomannan. The composition can provide both a protecting and a healing effect on mucosal surface.
摘要翻译： 通过组合藻酸盐，黄原胶和/或角叉菜胶和葡甘露聚糖和/或半乳甘露聚糖来制备具有改善的生物粘附性质的药物组合物。 该组合物可以提供对粘膜表面的保护和愈合作用。
-
4.发明授权公开(公告)号：US06306789B1
公开(公告)日：2001-10-23
申请号：US09416400
申请日：1999-10-12
申请人： Peter William Dettmar , Paul Andrew Dickson , Frank Chadwick Hampson , Ian Gordon Jollife , William Peers
发明人： Peter William Dettmar , Paul Andrew Dickson , Frank Chadwick Hampson , Ian Gordon Jollife , William Peers
IPC分类号： A61K950
CPC分类号： A61K31/195 , A61K9/0056 , A61K9/1635 , A61K9/1652 , A61K9/2077 , A61K31/66 , A61K2300/00
摘要： Mucoadhesive granules comprising a) carbomer and/or a salt thereof; and b) an inert filler. The granules preferably further comprise a pharmaceutically active agent suitable for sustained release into the gastrointestinal tract or for targeted delivery to the gastrointestinal mucosa.
摘要翻译： 包含a）卡波姆和/或其盐的粘膜粘合剂颗粒; 和b）惰性填料。颗粒优选还包含适于持续释放到胃肠道中或用于靶向递送至胃肠粘膜的药学活性剂。
-
公开(公告)号：US06391294B1
公开(公告)日：2002-05-21
申请号：US09485771
申请日：2000-04-12
IPC分类号： A61K3174
CPC分类号： A61K9/0065 , A61K9/0014 , A61K9/006 , A61K9/06 , A61K9/2086 , A61K9/4866 , A61K9/7015 , A61K47/32 , A61K47/36 , A61L26/0076 , C08J3/246 , C08L5/04 , C08L5/08 , C09D105/00
摘要： A pharmaceutically acceptable bio-adhesive coating, film or gel is formed in situ at a body surface by the reaction of (i) an anionic polymer or tripolyphosphate and (ii) a cationic polymer in the presence of water. The two components are supplied either as separate aqueous solutions or in a single non-aqueous formulation, which can be a liquid suspension tablet, capsule or powder.
摘要翻译： 通过（i）阴离子聚合物或三聚磷酸盐和（ii）在水存在下的阳离子聚合物的反应，在身体表面原位形成药学上可接受的生物粘合剂涂层，膜或凝胶。 两种组分作为单独的水溶液或单一非水性制剂提供，其可以是液体悬浮液片剂，胶囊或粉剂。
-
公开(公告)号：US06348502B1
公开(公告)日：2002-02-19
申请号：US09719129
申请日：2001-04-04
IPC分类号： A61K3116
CPC分类号： A61K9/0065 , A61K9/006 , A61K9/5036 , A61K31/12 , A61K31/165 , A61K31/357 , A61K31/4525
摘要： Formulations for the treatment of gastro-oesophageal reflux diseases include a carrier vehicle and an active gastro-protective agent. The carrier vehicle is either capable of forming a floating barrier layer on contact with gastric acid or of forming a bioadhesive film before any contact with gastric acid, so as to protect gastric mucosa from irritation by the gastric acid. A preferred active ingredient is capsaicin. The carrier vehicle preferably contains alginate or cross-linked polyacrylic acid.
摘要翻译： 用于治疗胃食管反流疾病的制剂包括载体载体和活性胃保护剂。 载体载体在与胃酸接触之前能够形成与胃酸接触的浮动屏障层或在与胃酸接触之前形成生物粘附膜，以保护胃粘膜免受胃酸的刺激。 优选的活性成分是辣椒素。 载体载体优选含有藻酸盐或交联的聚丙烯酸。
-
公开(公告)号：US20110064815A1
公开(公告)日：2011-03-17
申请号：US12989116
申请日：2009-04-23
CPC分类号： A61K33/00
摘要： There is provided a silica for use to inhibit a protease. In particular there is provided a silica for treatment or prevention of a disease or condition associated with adverse protease activity or adverse proteolytic degradation within the gastrointestinal tract.
摘要翻译： 提供了用于抑制蛋白酶的二氧化硅。 特别地，提供了用于治疗或预防与胃肠道内不利的蛋白酶活性或不利的蛋白水解降解相关的疾病或病症的二氧化硅。
-
公开(公告)号：US07288225B2
公开(公告)日：2007-10-30
申请号：US10258894
申请日：2001-05-10
IPC分类号： A61L2/08
CPC分类号： A61K36/68
摘要： Ispaghula (material from the plant Plantago ovata, useful as an agent in relieving constipation, is subjected to treatment with -radiation at a dose of up to 13 kGy, and preferably in the range 5-10 kGy. As well as effecting sterilisation of the ispaghula, this dose of irradiation has been shown to offer surprising rheological advantages.
摘要翻译： Ispaghula（来自植物车前草的物种，可用作缓解便秘的药剂，以高达13kGy的剂量进行辐射治疗，优选在5-10kGy的范围内，以及对 ispaghula，该剂量的照射已被证明具有令人惊奇的流变学优点。
-
公开(公告)号：US20120302521A1
公开(公告)日：2012-11-29
申请号：US13512118
申请日：2010-11-25
申请人： Johnathan Craig Richardson , Peter William Dettmar , Matthew David Wilcox , Iain Andrew Brownlee , Jeffrey Peter Pearson
发明人： Johnathan Craig Richardson , Peter William Dettmar , Matthew David Wilcox , Iain Andrew Brownlee , Jeffrey Peter Pearson
IPC分类号： A61K31/734 , A61P3/04 , C12N9/99
CPC分类号： A61K31/734
摘要： The present invention provides the use of an alginate Io inhibit pancreatic lipase. The use may be directed to the control of weight in animals including human beings. Preferably the fraction of guluronate dimers in the alginate is at least 0.5.
摘要翻译： 本发明提供藻酸盐抑制胰脂肪酶的用途。 该用途可以针对包括人在内的动物的体重控制。 优选地，藻酸盐中古洛糖醛酸二聚体的分数至少为0.5。
-
公开(公告)号：US09402858B2
公开(公告)日：2016-08-02
申请号：US13512118
申请日：2010-11-25
申请人： Johnathan Craig Richardson , Peter William Dettmar , Matthew David Wilcox , Iain Andrew Brownlee , Jeffrey Peter Pearson
发明人： Johnathan Craig Richardson , Peter William Dettmar , Matthew David Wilcox , Iain Andrew Brownlee , Jeffrey Peter Pearson
IPC分类号： A61K31/734
CPC分类号： A61K31/734
摘要： The present invention provides the use of an alginate Io inhibit pancreatic lipase. The use may be directed to the control of weight in animals including human beings. Preferably the fraction of guluronate dimers in the alginate is at least 0.5.
摘要翻译： 本发明提供藻酸盐抑制胰脂肪酶的用途。 该用途可以针对包括人在内的动物的体重控制。 优选地，藻酸盐中古洛糖醛酸二聚体的分数至少为0.5。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.033 秒)
